Gamida Cell Ltd.

Equities

GMDA

IL0011552663

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 12:14:45 2024-03-28 pm EDT 5-day change 1st Jan Change
0.039 USD -34.12% Intraday chart for Gamida Cell Ltd. -90.25% -90.48%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall MT
Top Premarket Decliners MT
Top Midday Decliners MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data MT
Transcript : Gamida Cell Ltd., Q4 2023 Earnings Call, Mar 27, 2024
US Futures Trend Higher Wednesday Pre-Bell as Investors Eye Impending Economic, Inflation Data Readings MT
Top Premarket Decliners MT
Gamida Cell Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Gamida Cell Ltd. announced that it expects to receive $30 million in funding from Highbridge Capital Management, LLC CI
JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform MT
Gamida Cell Exploring Strategic Alternatives; Shares Rise MT
Gamida Cell Actively Pursuing Strategic Alternatives CI
Transcript : Gamida Cell Ltd. - Special Call
Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating MT
HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating MT
Gamida Cell Ltd. Announces Resignation of Mr. Jeremy Blank as Board of Director CI
Transcript : Gamida Cell Ltd., Q3 2023 Earnings Call, Nov 14, 2023
Gamida Cell Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer Annual Meeting CI
Transcript : Gamida Cell Ltd. - Shareholder/Analyst Call
Gamida Cell Reports New Early Data in Phase 1 Study of Cancer Treatment Candidate MT
Gamida Cell Ltd. Reports Preliminary Data from Phase 1 Study of Natural Killer Cell Therapy Candidate GDA-201 CI
Gamida Cell Ltd. Announces First Patient Receives Omisirge (Omidubicel-Onlv) CI
Gamida Cell Ltd.(NasdaqGM:GMDA) added to S&P Global BMI Index CI
Transcript : Gamida Cell Ltd., Q2 2023 Earnings Call, Aug 14, 2023
Chart Gamida Cell Ltd.
More charts
Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies. The following are the Company's clinical pipeline products: NiCord, which is evaluated in a Phase III study in patients with high-risk blood cancers as well as in a Phase SS study in patients with severe aplastic anemia, as well as NAM-NK, an innate immunotherapy for the treatment of hematologic and solid tumors, which is investigated in a Phase I investigator-sponsored trial for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL), and multiple myeloma (MM).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.0592 USD
Average target price
5.5 USD
Spread / Average Target
+9,190.54%
Consensus
  1. Stock
  2. Equities
  3. Stock Gamida Cell Ltd. - Nasdaq
  4. News Gamida Cell Ltd.
  5. Gamida Cell Appoints Abigail Jenkins as President, CEO